LAUSR

Objective: The objective of the study is to compare computed tomography (CT)-based I125 radioactive seed brachytherapy (RSB) joint three-dimensional conformal radiotherapy (3D-CRT) and stereotactic ablative radiotherapy (SBRT) on early nonsmall cell lung cancer (NSCLC). Methods: The study involved 30 Stage I and II NSCLC patients from March 2014 to June 2017. The patients were divided into two groups: 20 cases with CT-based RSB–3D-CRT (300 cGy × 10) (Group A) and 10 cases with SBRT (8 cGy × 6) (Group B). Their local control rates, 1-year survival rates, and toxic and side effects were compared. Results: The median time of follow-up was 20 months (3–51 months). The 1-year local control rate in Groups A and B was 90% and 80%, respectively (P = 0.70). The 1-year survival rate in Groups A and B was 90% and 90%, respectively (P = 1.00). The indicator of radioactive pneumonia V20 and V30 in Groups A and B was 6.06% and 4.207%, and 11.32% and 7.111%, respectively (P = 0.000024 and 0.00090). Conclusion: Compared with SBRT, RSB–3D-CRT was more aggressive on early NSCLC. It remarkably reduced the indicators (V20 and V30) and the incidence of radioactive pneumonia.